Trial Profile
A randomized phase II study of concomitant chemoradiotherapy with 5-fluorouracil/hydroxyurea [hydroxycarbamide] compared to FHX plus bevacizumab for intermediate stage and selected stage IV cancers of the head and neck
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 24 Sep 2012
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Fluorouracil; Hydroxycarbamide
- Indications Head and neck cancer
- Focus Biomarker; Therapeutic Use
- 09 Jun 2011 Planned End Date changed from 1 Dec 2009 to 1 Jan 2013 as reported by ClinicalTrials.gov.
- 17 Feb 2011 Status changed from active, no longer recruiting to discontinued.
- 17 Feb 2011 This trial was halted following unexpected locoregional progression in the bevacizumab group in patients with T4N0-1 tumours